Showing 5641-5650 of 9179 results for "".
- Biofrontera Acquires Cutanea Life Scienceshttps://practicaldermatology.com/news/biofrontera-acquires-cutanea-life-sciences/2459959/Biofrontera Inc., USA entered into an agreement to acquire all shares in Cutanea Life Sciences, Inc., USA through its subsidiary Biofrontera Newderm LLC as the acquirer, with Maruho Co., Ltd., Japan as the seller. Maruho holds approximately 20 percent of Biofrontera AG. Cutanea is a US-based phar
- Biofrontera Reports Positive Phase 3 Results with Ameluz for PDT of AKs on Extremities and Trunk/Neckhttps://practicaldermatology.com/news/biofrontera-reports-positive-phase-3-results-with-ameluz-for-pdt-of-aks-on-extremities-and-trunkneck/2459961/Results for the primary endpoint of Biofrontera AG's Phase 3 clinical trial evaluating the safety and efficacy of conventional photodynamic therapy (PDT) with Ameluz and the BF-RhodoLED lamp for the treatment of actinic keratoses (AK) on the extremities as well as the trunk and neck are posti
- Jean Bolognia, MD Honored with AAD Gold Medalhttps://practicaldermatology.com/news/jean-bolognia-md-honored-with-aad-gold-medal/2459966/During the 2019 Annual Meeting of the American Academy of Dermatology (AAD) in Washington, D.C., the AAD awarded Jean Bolognia, MD, Professor of Dermatology at the Yale University School of Medicine, with its Gol
- AAD Announces 2019 Election Resultshttps://practicaldermatology.com/news/aad-announces-2019-election-results/2459967/The votes have been counted in the 2019 AAD Election, and the following candidates will take office at the conclusion of the 2020 Annual Meeting in Denver, Colorado on March 24, 2020.
- Dermira's Investigational AD Drug Performs Well in Phase 2b Trial, Shares Skyrockethttps://practicaldermatology.com/news/ready-for-phase-3-dermiras-investigational-ad-drug-performs-well-in-phase-2b-trial/2459969/All three doses of Dermira, Inc.’s lebrikizumab showed greater improvements in the Eczema Area and Severity Index in a new Phase 2b dose-ranging study of adults with moderate-to-severe atopic dermatitis, and shares of D
- Study: Port Wine Stain Laser Treatment Is Safe and Effective in Infants Without Anesthesiahttps://practicaldermatology.com/news/study-port-wine-stain-laser-treatment-is-safe-and-effective-in-infants-without-anesthesia/2459974/Recent concerns about the repetitive use of general anesthesia in children younger than 3 have placed greater importance on the controversy surrounding the timing of port-wine stain laser treatment, but a new
- History of Dermatology Society Names Samuel J. Zakon Awardeehttps://practicaldermatology.com/news/history-of-dermatology-society-names-samuel-j-zakon-awardee/2459972/Frederick C. Gaede, BA, MAS, has received the Samuel J. Zakon Award in the History of Dermatology for his article entitled “Henry Granger Piffard, MD and His Photogenic Pistol Cartridges.” The Award was announced at the forty-sixth annual meeting of the History of Dermatology Society
- Calling All Students: Ortho Dermatologics Now Accepting Applications for the 2019 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/calling-all-students-ortho-dermatologics-now-accepting-applications-for-the-2019-aspire-higher-scholarship-program/2459978/Ortho Dermatologics is accepting applications for its 2019 Aspire Higher scholarship program, which will award $90,000 total in scholarships to nine students who have been treated for a dermatologic condition. Students can apply for the Aspire Higher scholarship through April 26, 2
- FDA Approves Dupixent for Moderate to Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-approves-dupixent-for-moderate-to-severe-atopic-dermatitis-in-adolescents/2459975/The FDA has approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 through 17 whose disease is not adequately controlled with topical prescription
- 2019 NewBeauty Awards: Alastin's TransFORM Body Treatment Acknowledged for Innovationhttps://practicaldermatology.com/news/2019-newbeauty-awards-alastins-transform-body-treatment-acknowledged-for-innovation/2459977/ALASTIN Skincare, Inc’s TransFORM Body Treatment has been awarded a 2019 NewBeauty Award in the innovations category. NewBeauty acknowledges the best products, treatments and trends in cosmetics and aesthetics with their innovation category described as, "the future is now